Details

Autor(en) / Beteiligte

• Ghofrani, Hossein-Ardeschir
• Galiè, Nazzareno
• Grimminger, Friedrich
• Grünig, Ekkehard
• Humbert, Marc
• Jing, Zhi-Cheng
• Keogh, Anne M
• Langleben, David
• Kilama, Michael Ochan
• Fritsch, Arno
• Neuser, Dieter
• Rubin, Lewis J

Titel

Riociguat for the Treatment of Pulmonary Arterial Hypertension

Ist Teil von

• The New England journal of medicine, 2013-07, Vol.369 (4), p.330-340

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• In this trial, 443 patients with pulmonary arterial hypertension were assigned to placebo or to the soluble guanylate cyclase stimulator riociguat. At 12 weeks, riociguat significantly improved the 6-minute walk distance and pulmonary vascular resistance. Pulmonary arterial hypertension is a life-threatening disease that is characterized by increased pulmonary vascular resistance owing to progressive vascular remodeling, which can ultimately lead to right heart failure and death. 1 , 2 Current treatments include phosphodiesterase type 5 inhibitors, prostanoids, and endothelin-receptor antagonists. 1 However, mortality remains high despite treatment, 3 and there is a considerable unmet medical need in the management of this disorder. As noted elsewhere in this issue of the Journal, 4 riociguat is a member of a novel therapeutic class known as soluble guanylate cyclase stimulators. Riociguat has a dual mode of action, acting in synergy with endogenous nitric oxide . . .